Immix Biopharma Inc (IMMX US)

Health CareUnited States
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a novel class of tissue-specific therapeutics in oncology and inflammation to treat inflammatory bowel disease, including ulcerative colitis and crohn's diseases. Immix Biopharma serves customers in the United States.
03 Apr 2024 19:10Issuer-paid

Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T

Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with...

26 Mar 2024 19:10Issuer-paid

Immix Biopharma - Marching towards US clinical trials for NXC-201

Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer...

27 Feb 2024 19:10Issuer-paid

Immix Biopharma - 2023 recap with a preview of active year ahead

IMMX has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T...

13 Feb 2024 01:10Issuer-paid

Immix Biopharma - Updates galore: NXC-201 ODD (EU) and raise

Immix Biopharma has released back-to-back updates, including EU orphan drug designation (ODD) for its lead CAR-T asset NXC-201, addressing amyloid...

07 Feb 2024 19:10Issuer-paid

Immix Biopharma - Increased legroom following common-only raise

Immix Biopharma has announced a $15m (gross), fully underwritten equity issue. The company will use the proceeds to fund clinical trials for lead...